BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Merck and Mycenax Biotech Forge Partnership for Bioprocessing Innovation

Merck announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies Integrates company&rsq...

January 24, 2024 | News

WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...

January 24, 2024 | News

Sagimet Biosciences Reports Positive Results in Phase 2b Trial of Denifanstat for F2/F3 NASH

- Primary efficacy endpoints: NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD Activity Score) in ...

January 24, 2024 | News

First Myeloma Patient Treated with CAR-T Successfully Released

The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target treatment,...

January 23, 2024 | News

InnoCare Prescribes Tafasitamab Combo for Diffuse Large B-Cell Lymphoma in Greater Bay Area's Early Access Program

The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been appr...

January 22, 2024 | News

Sanyou Introduces Super Trillion Peptide Molecule Discovery Platform

The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Plat...

January 20, 2024 | News

CARsgen's CT011 Granted NMPA IND Clearance for GPC3-Positive Stage Ⅲa Liver Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

January 16, 2024 | News

WuXi Biologics and BioNTech Partner on Monoclonal Antibody Research Agreement

Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms (R in CRDMO) to discover two undisclosed...

January 11, 2024 | News

WuXi AppTec Triples Peptide Capacity, Launches Taixing API Site

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech an...

January 09, 2024 | News

The pioneering clinical implementation of Base Editing Therapy for Hemoglobinopathy on a global scale

On January 8, 2024, Shanghai,China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE...

January 09, 2024 | News

OBI Pharma's partner Biosion announces FDA clearance for the Phase 1/2 study of OBI-992 (TROP2 ADC)

First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...

January 09, 2024 | News

Akeso's Cadonilimab Granted NMPA Acceptance for First-Line Gastric Cancer Treatment.

This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...

January 08, 2024 | News

Kexing Biopharm Expands Global Portfolio with Eribulin Mesylate Injection

Eribulin Mesylate Injection is indicated for patients with locally advanced or metastatic breast cancer who have undergone at least two chemotherapy r...

January 08, 2024 | News

Belief BioMed Completes First Dosing in Hemophilia A Trial

BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...

January 04, 2024 | News

Stay Connected